Welcome to our dedicated page for Kenvue news (Ticker: KVUE), a resource for investors and traders seeking the latest updates and insights on Kenvue stock.
Kenvue Inc. (NYSE: KVUE) is described as the world’s largest pure-play consumer health company by revenue, with a portfolio of science-backed brands such as Aveeno®, BAND-AID® Brand, Johnson’s®, Listerine®, Neutrogena®, Tylenol® and Zyrtec®. This news page aggregates company announcements, press releases and market-moving updates related to KVUE stock and Kenvue’s global consumer health operations.
Readers can find earnings news, including quarterly results where Kenvue reports net sales trends, organic sales performance, gross profit and operating income margins, and diluted and adjusted earnings per share. These releases often include management commentary on operating priorities, productivity initiatives, supply chain optimization efforts and updated outlooks for the fiscal year, along with explanations of non-GAAP measures such as Adjusted gross profit margin, Adjusted operating income margin, Adjusted net income, Adjusted EBITDA margin, Adjusted effective tax rate, Free cash flow and Organic sales.
The feed also covers strategic and corporate developments. In 2025, Kenvue announced a comprehensive review of strategic alternatives, leadership changes including a CEO transition, and a definitive agreement under which Kimberly-Clark Corporation will acquire all outstanding shares of Kenvue common stock in a cash and stock transaction, as detailed in joint press releases and a Form 8-K. Updates on this planned acquisition, board decisions and related shareholder communications are key topics for investors following KVUE news.
Additional items include dividend declarations by Kenvue’s Board of Directors, highlighting the company’s approach to returning capital to shareholders, and partnership and innovation news, such as the collaboration with Albert Invent to apply AI to Kenvue’s research and development processes. Together, these categories give investors, analysts and consumers a consolidated view of how Kenvue manages its brand portfolio, financial performance and strategic direction. Bookmark this page to quickly access the latest official Kenvue updates relevant to KVUE stock.
Kenvue (NYSE: KVUE) reported Q1 2026 results: net sales +4.5%, organic sales +0.7%, diluted EPS $0.25 (+47%), adjusted diluted EPS $0.32 (+33%). Gross margin expanded to 58.9% and adjusted gross margin to 60.8%. Operating margin widened to 19.6% and adjusted operating margin to 24.0%. Free cash flow rose to $0.4 billion. The company reaffirmed the expected close of its Kimberly-Clark transaction in H2 2026, subject to regulatory approvals, and disclosed a 2026 restructuring charge of about $250 million.
Kenvue (NYSE: KVUE) announced a quarterly cash dividend of $0.2075 per share. The dividend is payable on May 27, 2026 to shareholders of record at the close of business on May 13, 2026. Contact information for investor and media relations was provided.
Kenvue (NYSE: KVUE) will announce its first quarter 2026 financial results before market open on May 7, 2026. Due to a pending transaction with Kimberly-Clark, Kenvue will not host a quarterly conference call.
The press release will be posted on the company's investor website at investors.kenvue.com. Investor and media contact emails are provided for follow-up.
Kimberly-Clark (NASDAQ: KMB) announced the post-closing organizational structure and named key leaders that will take effect after completing its pending acquisition of Kenvue, targeted to close in the second half of 2026. The combined company will operate four segments with estimated annual sales: North America $18.0B, EMEA $5.0B, Asia Pacific Focus Markets $4.3B, and Enterprise Markets $4.3B.
Mike Hsu will remain Chairman and CEO; a senior leadership roster and integration management office were disclosed to drive Day 1 readiness and identify growth and efficiency priorities.
Kenvue (NYSE:KVUE) reported Q4 2025 net sales +3.2% and organic sales +1.2%, with Q4 diluted EPS $0.17 and adjusted diluted EPS $0.27. Full year 2025 net sales declined 2.1% with diluted EPS $0.76 and adjusted diluted EPS $1.08. The company expects the Kimberly-Clark acquisition to close in H2 2026, subject to approvals.
Free cash flow rose to $1.7 billion and total debt was $8.5 billion as of December 28, 2025.
Kenvue (NYSE: KVUE) will report fourth quarter and full year 2025 results after market close on February 17, 2026. Due to the pending transaction with Kimberly-Clark, Kenvue will not host a quarterly conference call; the press release will be posted at the company investor website.
Investor and media contacts are provided for follow-up.
Kimberly-Clark (NASDAQ: KMB) and Kenvue (NYSE: KVUE) reported that shareholders at special meetings overwhelmingly approved the proposed acquisition of Kenvue by Kimberly-Clark.
Preliminary voting showed ~96% of shares at Kimberly-Clark approved issuance of Kimberly-Clark stock and ~99% of votes at Kenvue adopted the merger agreement (about 77% of outstanding Kenvue shares). The transaction is expected to close in the second half of 2026, subject to regulatory approvals and customary closing conditions.
Kenvue (NYSE: KVUE) declared a quarterly cash dividend of $0.2075 per share. The dividend is payable on February 25, 2026 to shareholders of record at the close of business on February 11, 2026. This is a regular cash distribution on common stock.
The announcement lists investor and media contacts and describes Kenvue as a consumer health company with brands such as Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena and Tylenol.
Summary not available.
Kimberly-Clark (NASDAQ: KMB) agreed to acquire Kenvue (NYSE: KVUE) in a cash-and-stock transaction valuing Kenvue at an enterprise value of approximately $48.7 billion (based on KMB close on Oct 31, 2025). The deal offers Kenvue shareholders $3.50 cash plus 0.14625 KMB shares (total $21.01 per KVUE share) and is expected to close in H2 2026, subject to approvals.
The combined company is projected to generate ~$32 billion revenue and ~$7 billion adjusted EBITDA in 2025, with anticipated run-rate synergies of $2.1 billion and $2.5 billion of one-time costs to capture them. Post-close ownership: ~54% KMB / 46% KVUE.